Incyte, Merck shares slide after melanoma therapy fails study

Investing


Emile Wamsteker | Bloomberg | Getty Images

Pedestrians walk across the street from a Merck & Co. facility in Summit, New Jersey

Incyte said on Friday an independent committee concluded that its drug for a type of skin cancer in combination with Merck‘s Keytruda failed to meet the main goal in a late-stage study.

Incyte shares fell 20 percent in premarket trading Friday, while Merck shares were down about 2 percent.

The two companies would stop the study as it did not meet the primary goal of improving progression-free survival compared to patients on Keytruda monotherapy.

Merck’s Keytruda is approved for the treating several forms of cancer, including lung cancer and advanced melanoma. The companies said the study’s second main goal of overall survival was also not expected to reach a statistical significance.

The study was evaluating a combination of Incyte’s inhibitor Epacadostat and Merck’s Keytruda for the treatment of metastatic melanoma.



Source link

Products You May Like

Articles You May Like

DOJ can ‘follow the coyote off a cliff’ in AT&T appeal
Amazon Web Services said to eye network devices, networking stocks tank
Wall Street’s top economist Hyman calls Trump’s trade tactics classic ‘Art of the Deal’
Downgrades FedEx on trade risk, upgrades UPS on domestic delivery
President Nixon’s speech if Apollo 11 had been stranded on the moon

Leave a Reply

Your email address will not be published. Required fields are marked *